Effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome: A perspective, randomized, placebo-controlled study

Menopause

Volumn 18, Issue 1, 2011, Pages 102-104

  Giordano, Domenico ^a   Corrado, Francesco ^b   Santamaria, Angelo ^b   Quattrone, Simona ^a   Pintaudi, Basilio ^c   Di Benedetto, Antonino ^c   D'Anna, Rosario ^b  

^a Policlinico Hospital   (Italy)

^b Departments of Obstetrics and Gynecological Sciences   (United States)

^c UNIVERSITY OF MESSINA   (Italy)

Author keywords

Homeostasis model assessment ratio; Metabolic syndrome; Myo inositol; Postmenopause

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INOSITOL; INSULIN SENSITIZING AGENT; PLACEBO; TRIACYLGLYCEROL;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DIET SUPPLEMENTATION; FEMALE; HOMEOSTASIS; HUMAN; HYPERLIPIDEMIA; HYPERMETABOLISM; HYPERTENSION; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; FEMALE; HUMANS; INOSITOL; INSULIN; INSULIN RESISTANCE; LIPIDS; METABOLIC SYNDROME X; MIDDLE AGED; POSTMENOPAUSE; PROSPECTIVE STUDIES;

EID: 78651404451     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e3181e8e1b1     Document Type: Article

References (12)

1. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24:683-689.
2. Sowers JR, Epstein M, Froholich ED. Diabetes, hypertension, and cardiovascular disease. An update. Hypertension 2001;37:1053-1059.
3. Nestler JE, Jakubowicz DJ, Reamer P, Gunn RD, Allan G. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. N Engl J Med 1999;340:1314-1320.
4. Genazzani AR, Lanzoni C, Ricchieri F, Jasonni VM. Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome. Gynecol Endocrinol 2008;24:139-144.
5. Saltiel AR. Second messengers of insulin action. Diabetes Care 1990; 13:244-256.
6. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
7. De Micheli A. Italian standards for diabetes mellitus 2007: executive summary: Diabete Italia, AMD Associazione Medici Diabetologi, SID Società Italiana di Diabetologia. Acta Diabetol 2008;45:107-127.
8. Haffner SM, Miettinem H, Stern MP. The homeostasis model in the San Antonio Hearth Study. Diabetes Care 1997;20:1087-1092.
9. Esposito K, Ciotola M, Carleo D, et al. Effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome. Diabetes Care 2006;29:1071-1076.
10. Orchard TJ, Temprosa M, Goldberg R, et al. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: The Diabetes Prevention Program Randomized Trial. Ann Intern Med 2005; 142:611-619.
11. Pedersen O. Genetics of insulin resistance. Exp Clin Endocrinol Diabetes 1999;107:113-118.
12. Cheang KI, Baillargeon JP, Essah PA, et al. Insulin-stimulated release of D-chiro-inositol-containing inositolphosphoglycan mediator correlates with insulin sensitivity in women with polycystic ovary syndrome. Metabolism 2008;57:1390-1397.